Teng Kuang Yeh - JoVE Visualize

Showing results (71-80 of 128) with videos related to

Pageof 13

Sort By:

Journal of Medicinal Chemistry|April 29, 2014

Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cellsHsueh-Yun Lee, An-Chi Tsai, Mei-Chuan Chen, et al.

Journal of Controlled Release : Official Journal of the Controlled Release Society|January 25, 2025

CXCR4 antagonist-loaded nanoparticles reprogram the tumor microenvironment and enhance immunotherapy in hepatocellular carcinomaSheng-Liang Cheng, Chien-Huang Wu, Yun-Jen Tsai, et al.

Chemmedchem|September 5, 2006

Structure-activity relationship studies of 3-aroylindoles as potent antimitotic agentsJing-Ping Liou, Neeraj Mahindroo, Chun-Wei Chang, et al.

Chemical Research in Toxicology|August 15, 2015

Novel Nrf2/ARE activator, trans-Coniferylaldehyde, induces a HO-1-mediated defense mechanism through a dual p38α/MAPKAPK-2 and PK-N3 signaling pathwayHuang-Hui Chen, Tai-Chi Wang, Yen-Chen Lee, et al.

Biomedical Journal|May 20, 2020

Artificial intelligence approach fighting COVID-19 with repurposing drugsYi-Yu Ke, Tzu-Ting Peng, Teng-Kuang Yeh, et al.

Biochemical Pharmacology|May 15, 2009

Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitorJia-Jing Wu, Hung-Kuan Tang, Teng-Kuang Yeh, et al.

Anesthesiology|February 18, 2017

1-(2,4-Dibromophenyl)-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one: A Novel Opioid Receptor Agonist with Less Accompanying Gastrointestinal Dysfunction than MorphinePo-Kuan Chao, Shau-Hua Ueng, Li-Chin Ou, et al.

International Journal of Molecular Sciences|October 14, 2022

Protective Effect of CXCR4 Antagonist DBPR807 against Ischemia-Reperfusion Injury in a Rat and Porcine Model of Myocardial Infarction: Potential Adjunctive Therapy for Percutaneous Coronary InterventionKai-Chia Yeh, Chia-Jui Lee, Jen-Shin Song, et al.

Translational Oncology|October 17, 2020

BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapyYun-Yu Chen, Chen-Fu Lo, Tai-Yu Chiu, et al.

Journal of Medicinal Chemistry|October 4, 2021

Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor ModelKun-Hung Lee, Wan-Ching Yen, Wen-Hsing Lin, et al.

Pageof 13

Showing results (71-80 of 128) with videos related to

Sort By:

Pageof 13

Journal of Medicinal Chemistry|April 29, 2014

Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cellsHsueh-Yun Lee, An-Chi Tsai, Mei-Chuan Chen, et al.

Journal of Controlled Release : Official Journal of the Controlled Release Society|January 25, 2025

CXCR4 antagonist-loaded nanoparticles reprogram the tumor microenvironment and enhance immunotherapy in hepatocellular carcinomaSheng-Liang Cheng, Chien-Huang Wu, Yun-Jen Tsai, et al.

Chemmedchem|September 5, 2006

Structure-activity relationship studies of 3-aroylindoles as potent antimitotic agentsJing-Ping Liou, Neeraj Mahindroo, Chun-Wei Chang, et al.

Chemical Research in Toxicology|August 15, 2015

Novel Nrf2/ARE activator, trans-Coniferylaldehyde, induces a HO-1-mediated defense mechanism through a dual p38α/MAPKAPK-2 and PK-N3 signaling pathwayHuang-Hui Chen, Tai-Chi Wang, Yen-Chen Lee, et al.

Biomedical Journal|May 20, 2020

Artificial intelligence approach fighting COVID-19 with repurposing drugsYi-Yu Ke, Tzu-Ting Peng, Teng-Kuang Yeh, et al.

Biochemical Pharmacology|May 15, 2009

Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitorJia-Jing Wu, Hung-Kuan Tang, Teng-Kuang Yeh, et al.

Anesthesiology|February 18, 2017

1-(2,4-Dibromophenyl)-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one: A Novel Opioid Receptor Agonist with Less Accompanying Gastrointestinal Dysfunction than MorphinePo-Kuan Chao, Shau-Hua Ueng, Li-Chin Ou, et al.

International Journal of Molecular Sciences|October 14, 2022

Protective Effect of CXCR4 Antagonist DBPR807 against Ischemia-Reperfusion Injury in a Rat and Porcine Model of Myocardial Infarction: Potential Adjunctive Therapy for Percutaneous Coronary InterventionKai-Chia Yeh, Chia-Jui Lee, Jen-Shin Song, et al.

Translational Oncology|October 17, 2020

BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapyYun-Yu Chen, Chen-Fu Lo, Tai-Yu Chiu, et al.

Journal of Medicinal Chemistry|October 4, 2021

Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor ModelKun-Hung Lee, Wan-Ching Yen, Wen-Hsing Lin, et al.

Pageof 13